Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Akebia Therapeutics Inc (NASDAQ: AKBA) closed at $3.64 in the last session, down -0.27% from day before closing price of $3.65. In other words, the price has decreased by -$0.27 from its previous closing price. On the day, 2.85 million shares were traded. AKBA stock price reached its highest trading level at $3.74 during the session, while it also had its lowest trading level at $3.63.
Ratios:
We take a closer look at AKBA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.02 and its Current Ratio is at 2.23. In the meantime, Its Debt-to-Equity ratio is 8.39 whereas as Long-Term Debt/Eq ratio is at 7.41.
On April 28, 2025, Leerink Partners started tracking the stock assigning a Outperform rating and target price of $7.
On April 01, 2025, Jefferies started tracking the stock assigning a Buy rating and target price of $6.Jefferies initiated its Buy rating on April 01, 2025, with a $6 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jun 30 ’25 when Ostrowski Erik bought 41,314 shares for $3.67 per share.
Malabre Richard C sold 15,000 shares of AKBA for $60,150 on Jun 09 ’25. The SVP, Chief Accounting Officer now owns 266,914 shares after completing the transaction at $4.01 per share. On Jun 04 ’25, another insider, Malabre Richard C, who serves as the SVP, Chief Accounting Officer of the company, sold 13,334 shares for $3.53 each. As a result, the insider received 47,069 and left with 266,914 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AKBA now has a Market Capitalization of 959944448 and an Enterprise Value of 1038216448. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.17 while its Price-to-Book (P/B) ratio in mrq is 38.74. Its current Enterprise Value per Revenue stands at 5.615 whereas that against EBITDA is 101.766.
Stock Price History:
The Beta on a monthly basis for AKBA is 0.88, which has changed by 2.7916667 over the last 52 weeks, in comparison to a change of 0.12632763 over the same period for the S&P500. Over the past 52 weeks, AKBA has reached a high of $4.08, while it has fallen to a 52-week low of $0.91. The 50-Day Moving Average of the stock is 22.23%, while the 200-Day Moving Average is calculated to be 72.06%.
Shares Statistics:
According to the various share statistics, AKBA traded on average about 5.06M shares per day over the past 3-months and 4927540 shares per day over the past 10 days. A total of 261.64M shares are outstanding, with a floating share count of 251.57M. Insiders hold about 4.21% of the company’s shares, while institutions hold 36.53% stake in the company. Shares short for AKBA as of 1749772800 were 18498837 with a Short Ratio of 3.66, compared to 1747267200 on 19722763. Therefore, it implies a Short% of Shares Outstanding of 18498837 and a Short% of Float of 7.12.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
